Back to Freestone Grove Partners LP Freestone Grove Partners LP

STOKSTOK

3 quarters

Position history for Freestone Grove Partners LPFreestone Grove Partners LP's holdings in Stoke Therapeutics, Inc.

No. Freestone Grove Partners exited its STOK (Stoke Therapeutics) position in Q2 2025. Its Q1 2025 13F listed 14,776 shares worth $98,260. Freestone Grove Partners already held STOK in its Q4 2024 13F, the earliest on record, and held it in 2 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$199,080

Total Shares Change

-18,049

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q2
Latest
Exited
0
-100.0%
$00.0%$11.35
0
2025-Q1
Decreased
14,776
-18.1%
$98,2600.0%$6.65
0
2024-Q4
First report
18,049
—
$199,0800.0%$11.03
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used